Nectar Lifesciences Ltd. AI Stock Analysis
Want to see IN:NECLIFE full AI Analyst Report?
Nectar Lifesciences Ltd. (NECLIFE) AI Stock Analysis
Nectar Lifesciences Ltd.
(NSE:NECLIFE)
Low score driven primarily by weak financial performance with revenue volatility and losses; positive technical momentum offers limited support while unattractive valuation constrains the rating.
Nectar Lifesciences Ltd. (NECLIFE) vs. iShares MSCI India ETF (INDA)
- Market Cap
- INR 1.94B
- Dividend Yield
- ―
- Average Volume (3M)
- 28.04K
- Price to Earnings (P/E)
- -2.9
- Beta (1Y)
- 1.28
- Revenue Growth
- -99.85%
- EPS Growth
- 78.93%
- Country
- India
- Employees
- 111
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Nectar Lifesciences Ltd. Business Overview & Revenue Model
Company Description
Nectar Lifesciences Limited, established in Chandigarh, India, in 1995, operates as a global pharmaceutical company involved in the production and distribution of medicinal products. The firm delivers extensive contract research and manufacturing ser...
How the Company Makes Money
Nectar Lifesciences Ltd. makes money primarily by selling pharmaceutical products to customers (typically including other pharmaceutical companies, distributors, and institutional buyers depending on the product category). Key revenue streams general...
Nectar Lifesciences Ltd. Financial Statement Overview
Summary
Volatile revenues, persistent net losses, declining assets and equity, with inconsistent cash flows despite debt reduction efforts.
Income Statement
25NegativeBalance Sheet
40NegativeCash Flow
45Neutral| Breakdown | TTM | Mar 2026 | Jun 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 74.43M | 20.11M | 16.70B | 16.84B | 15.24B | 16.69B |
| Gross Profit | -567.25M | -590.34M | 3.02B | 4.82B | 579.91M | 2.99B |
| EBITDA | 83.68M | -289.51M | -245.66M | 1.69B | 994.97M | 1.61B |
| Net Income | -2.45B | -2.93B | -1.14B | 49.95M | -241.83M | 250.47M |
Balance Sheet | ||||||
| Total Assets | 0 | 6.22B | 20.47B | 21.91B | 21.89B | 23.91B |
| Cash, Cash Equivalents and Short-Term Investments | 1.25B | 1.25B | 272.63M | 203.01M | 178.94M | 182.35M |
| Total Debt | 0 | 0 | 5.82B | 6.36B | 7.54B | 8.60B |
| Total Liabilities | -5.82B | 393.11M | 10.91B | 11.22B | 11.25B | 13.03B |
| Stockholders Equity | 5.82B | 5.82B | 9.56B | 10.69B | 10.65B | 10.88B |
Cash Flow | ||||||
| Free Cash Flow | 1.44B | -3.61B | 1.26B | 1.95B | 1.04B | 700.35M |
| Operating Cash Flow | 1.53B | -3.49B | 1.69B | 2.25B | 1.34B | 950.05M |
| Investing Cash Flow | -82.31M | 12.08B | -419.30M | -170.25M | 517.04M | 166.44M |
| Financing Cash Flow | -1.58B | -7.67B | -1.28B | -2.05B | -1.86B | -1.19B |
Nectar Lifesciences Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:NECLIFE, the sentiment is Negative. The current price of 9.98 is below the 20-day moving average (MA) of 10.32, below the 50-day MA of 10.67, and below the 200-day MA of 11.50, indicating a bearish trend. The MACD of -0.13 indicates Positive momentum. The RSI at 40.76 is Neutral, neither overbought nor oversold. The STOCH value of 18.58 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:NECLIFE.
Nectar Lifesciences Ltd. Peers Comparison
Overall Rating
IN:IOLCP72Outperform
IN:NEULANDLAB60Neutral
IN:GRANULES59Neutral
IN:HIKAL57Neutral
IN:SOLARA50Neutral
IN:NECLIFE47Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 72Outperform | INR 56.27B | 27.71 | ― | 0.52% | 26.76% | 75.41% | |
| 60Neutral | INR 270.62B | 59.83 | ― | 0.16% | 50.46% | 88.44% | |
| 59Neutral | INR 199.33B | 27.72 | ― | 0.22% | 21.75% | 36.70% | |
| 57Neutral | INR 27.35B | -555.15 | ― | 0.27% | 8.93% | -149.51% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | INR 30.74B | 82.98 | ― | ― | 27.30% | 456.80% | |
| 47Neutral | INR 1.94B | -2.94 | ― | ― | -99.85% | 78.93% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| IN:NECLIFE | Nectar Lifesciences Ltd. | 9.98 | -4.10 | -29.12% | |
| IN:GRANULES | Granules India Limited | 804.40 | 272.91 | 51.35% | |
| IN:HIKAL | Hikal Limited | 221.85 | 4.22 | 1.94% | |
| IN:IOLCP | IOL Chemicals & Pharmaceuticals Ltd. | 191.70 | 100.13 | 109.35% | |
| IN:NEULANDLAB | Neuland Laboratories Ltd. | 21092.60 | 4864.30 | 29.97% | |
| IN:SOLARA | Solara Active Pharma Sciences Ltd. | 639.30 | 116.95 | 22.39% |
Nectar Lifesciences Ltd. Corporate Events
Nectar Lifesciences Issues Revised AGM Proceedings, Receives Clean Audit for FY 2025-26
Nectar Lifesciences has issued revised proceedings for its 31st Annual General Meeting after correcting an inadvertent error in the cut-off date, reaffirming its adherence to SEBI listing regulations. The AGM was conducted on September 18, 2026 via v...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 27, 2026
